G protein-coupled receptors as therapeutic targets for multiple sclerosis

Cell Research

Volumn 22, Issue 7, 2012, Pages 1108-1128

  Du, Changsheng ^a   Xie, Xin ^a,b  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

agonist; antagonist; experimental autoimmune encephalomyelitis(EAE); G protein coupled receptors (GPCRs); multiple sclerosis (MS); therapeutic targets

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; METABOLISM; MULTIPLE SCLEROSIS; REVIEW;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, G-PROTEIN-COUPLED;

ANIMALIA;

EID: 84863458469     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2012.87     Document Type: Review

References (287)

1. McFarlin DE, McFarland HF. Multiple sclerosis (first of two parts). N Engl J Med 1982; 307:1183-1188. (Pubitemid 12037979)
2. McFarlin DE, McFarland HF. Multiple sclerosis (second of two parts). N Engl J Med 1982; 307:1246-1251. (Pubitemid 12001360)
3. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22:117-139.
4. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359:1221-1231. (Pubitemid 34304266)
5. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354:942-955.
6. Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2-T lymphocytes. J Immunol 1981; 127:1420-1423. (Pubitemid 11021014)
7. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23:683-747. (Pubitemid 40563183)
8. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-240. (Pubitemid 40189432)
9. Ivanov, II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:1121-1133. (Pubitemid 44380299)
10. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172:146-155. (Pubitemid 351186376)
11. McFarland HF. Correlation between MR and clinical findings of disease activity in multiple sclerosis. AJNR Am J Neuroradiol 1999; 20:1777-1778.
12. Raine CS, Scheinberg LC. On the immunopathology of plaque development and repair in multiple sclerosis. J Neuroimmunol 1988; 20:189-201. (Pubitemid 19008415)
13. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717. (Pubitemid 30390191)
14. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-1517.
15. Baranzini SE, Mudge J, van Velkinburgh JC, et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010; 464:1351-1356.
16. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22:368-376. (Pubitemid 32592476)
17. Allen JA, Roth BL. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2011; 51:117-144.
18. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991; 349:117-127. (Pubitemid 21912023)
19. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7:79-94. (Pubitemid 46164746)
20. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011; 10:47-60.
21. Mayne M, Shepel PN, Jiang Y, Geiger JD, Power C. Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol 1999; 45:633-639. (Pubitemid 29217592)
22. Johnston JB, Silva C, Gonzalez G, et al. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 2001; 49:650-658. (Pubitemid 32429792)
23. Tsutsui S, Schnermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004; 24:1521-1529. (Pubitemid 38223004)
24. Mills JH, Thompson LF, Mueller C, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008; 105:9325-9330.
25. Chen GQ, Chen YY, Wang XS, et al. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res 2010; 1309:116-125.
26. Milne GR, Palmer TM. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. Scientific-WorldJournal 2011; 11:320-339.
27. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7:759-770.
28. Montesinos MC, Gadangi P, Longaker M, et al. Wound healing is accelerated by agonists of adenosine A2 (G alpha slinked) receptors. J Exp Med 1997; 186:1615-1620. (Pubitemid 27479823)
29. Luijk B, van den Berge M, Kerstjens HA, et al. Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. Allergy 2008; 63:75-80. (Pubitemid 350198243)
30. Ledent C, Vaugeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997; 388:674-678. (Pubitemid 27366438)
31. Successful and effective: Montelukast in clinical practice. Internist 1999; 40(12 Suppl Montelukas):1-4.
32. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001; 61:443-448. (Pubitemid 32168226)
33. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007; 14:1315-1323. (Pubitemid 46965261)
34. Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol 2009; 30:263-270.
35. Kolachala V, Asamoah V, Wang L, et al. TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis. Cell Mol Life Sci 2005; 62:2647-2657. (Pubitemid 41721236)
36. Kolachala V, Ruble B, Vijay-Kumar M, et al. Blockade of adenosine A2B receptors ameliorates murine colitis. Br J Pharmacol 2008; 155:127-137.
37. Kolachala VL, Vijay-Kumar M, Dalmasso G, et al. A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology 2008; 135:861-870.
38. Lee JY, Jhun BS, Oh YT, et al. Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NFkappaB activation in murine BV2 microglial cells. Neurosci Lett 2006; 396:1-6. (Pubitemid 43233777)
39. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLRmediated TNF-alpha production in the human newborn. J Immunol 2006; 177:1956-1966. (Pubitemid 44092536)
40. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010; 2:817-833.
41. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57:1885-1888. (Pubitemid 33096700)
42. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis pa tients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531-1534. (Pubitemid 26422549)
43. TNF neutralization in MS: results of a randomized, placebocontrolled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53:457-465.
44. Varani K, Maniero S, Vincenzi F, et al. A receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-kappaB pathway. Am J Respir Crit Care Med 2011; 183:522-530.
45. Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007; 16:1601-1613. (Pubitemid 350028410)
46. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002; 20:125-163. (Pubitemid 34295785)
47. Straub RH. Complexity of the bi-directional neuroimmune junction in the spleen. Trends Pharmacol Sci 2004; 25:640-646. (Pubitemid 39458170)
48. Mackenzie FJ, Leonard JP, Cuzner ML. Changes in lymphocyte beta-adrenergic receptor density and noradrenaline content of the spleen are early indicators of immune reactivity in acute experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol 1989; 23:93-100. (Pubitemid 19144789)
49. Breneman SM, Moynihan JA, Grota LJ, Felten DL, Felten SY. Splenic norepinephrine is decreased in MRL-lpr/lpr mice. Brain Behav Immun 1993; 7:135-143. (Pubitemid 23222547)
50. Zoukos Y, Leonard JP, Thomaides T, Thompson AJ, Cuzner ML. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann Neurol 1992; 31:657-662.
51. Zoukos Y, Kidd D, Woodroofe MN, Kendall BE, Thompson AJ, Cuzner ML. Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994; 117(Pt 2):307-315. (Pubitemid 24155502)
52. Zoukos Y, Thomaides T, Mathias CJ, Cuzner ML. High betaadrenoceptor density on peripheral blood mononuclear cells in progressive multiple sclerosis: a manifestation of autonomic dysfunction? Acta Neurol Scand 1994; 90:382-387. (Pubitemid 24368990)
53. Zoukos Y, Thomaides TN, Kidd D, Cuzner ML, Thompson A. Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. J Neurol Neurosurg Psychiatry 2003; 74:197-202. (Pubitemid 36160680)
54. Karaszewski JW, Reder AT, Maselli R, Brown M, Arnason BG. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol 1990; 27:366-372. (Pubitemid 20132051)
55. Karaszewski JW, Reder AT, Anlar B, Kim WC, Arnason BG. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28-suppressor cell. Ann Neurol 1991; 30:42-47.
56. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol 1997; 158:4200-4210. (Pubitemid 127483920)
57. Seiffert K, Hosoi J, Torii H, et al. Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol 2002; 168:6128-6135. (Pubitemid 34620030)
58. Maestroni GJ. Short exposure of maturing, bone marrowderived dendritic cells to norepinephrine: impact on kinetics of cytokine production and Th development. J Neuroimmunol 2002; 129:106-114. (Pubitemid 34874915)
59. Maestroni GJ, Mazzola P. Langerhans cells beta 2-adrenoceptors: role in migration, cytokine production, Th priming and contact hypersensitivity. J Neuroimmunol 2003; 144:91-99. (Pubitemid 37329933)
60. Kim BJ, Jones HP. Epinephrine-primed murine bone marrowderived dendritic cells facilitate production of IL-17A and IL-4 but not IFN-gamma by CD4+ T cells. Brain Behav Immun 2010; 24:1126-1136.
61. De Keyser J, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 1999; 53:1628-1633. (Pubitemid 29530330)
62. Mantyh PW, Rogers SD, Allen CJ, et al. Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous system in the rat, rabbit, and human. J Neurosci 1995; 15:152-164.
63. Cohen Z, Molinatti G, Hamel E. Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J Cereb Blood Flow Metab 1997; 17:894-904. (Pubitemid 27377644)
64. Zeinstra E, Wilczak N, De Keyser J. [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci Lett 2000; 289:75-77. (Pubitemid 30433850)
65. Nikcevich KM, Gordon KB, Tan L, et al. IFN-gammaactivated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol 1997; 158:614-621. (Pubitemid 127492637)
66. Soos JM, Morrow J, Ashley TA, Szente BE, Bikoff EK, Zamvil SS. Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol 1998; 161:5959-5966. (Pubitemid 28535964)
67. Frohman EM, Vayuvegula B, Gupta S, van den Noort S. Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc Natl Acad Sci USA 1988; 85:1292-1296. (Pubitemid 18073995)
68. Frohman EM, Vayuvegula B, van den Noort S, Gupta S. Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes. J Neuroimmunol 1988; 17:89-101. (Pubitemid 18006107)
69. Gavrilyuk V, Horvath P, Weinberg G, Feinstein DL. A 27-bp region of the inducible nitric oxide synthase promoter regulates expression in glial cells. J Neurochem 2001; 78:129-140. (Pubitemid 32622595)
70. Gavrilyuk V, Dello Russo C, Heneka MT, Pelligrino D, Weinberg G, Feinstein DL. Norepinephrine increases I kappa B alpha expression in astrocytes. J Biol Chem 2002; 277:29662-29668.
71. De Keyser J, Laureys G, Demol F, Wilczak N, Mostert J, Clinckers R. Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. Neurochem Int 2010, 57:446-450.
72. Wiegmann K, Muthyala S, Kim DH, Arnason BG, Chelmicka-Schorr E. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats. J Neuroimmunol 1995; 56:201-206.
73. Makhlouf K, Weiner HL, Khoury SJ. Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs 2002; 16:1-8. (Pubitemid 34151334)
74. De Keyser J, Zeinstra E, Mostert J, Wilczak N. Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. Trends Pharmacol Sci 2004; 25:67-71. (Pubitemid 38183391)
75. De Keyser J, Zeinstra E, Wilczak N. Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol Dis 2004; 15:331-339. (Pubitemid 38296764)
76. Khoury SJ, Healy BC, Kivisakk P, et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol 2010; 67:1055-1061. 77 Brosnan CF, Goldmuntz EA, Cammer W, Factor SM, Bloom BR, Norton WT. Prazosin, an alpha 1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Proc Natl Acad Sci USA 1985; 82:5915-5919.
77. Goldmuntz EA, Brosnan CF, Chiu FC, Norton WT. Astrocytic reactivity and intermediate filament metabolism in experimental autoimmune encephalomyelitis: the effect of suppression with prazosin. Brain Res 1986; 397:16-26. (Pubitemid 17184821)
78. Brosnan CF, Sacks HJ, Goldschmidt RC, Goldmuntz EA, Norton WT. Prazosin treatment during the effector stage of disease suppresses experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1986; 137:3451-3456. (Pubitemid 17193299)
79. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother 2008; 9:2209-2215.
80. Kamen L, Henney HR 3rd, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008; 24:425-439. (Pubitemid 351294392)
81. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58:389-462. (Pubitemid 44394908)
82. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007; 152:567-575. (Pubitemid 350041541)
83. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152:1092-1101. (Pubitemid 350166046)
84. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50:193-211. 86 Demuth DG, Molleman A. Cannabinoid signalling. Life Sci 2006; 78:549-563.
85. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23:2511-2516. (Pubitemid 36418583)
86. Ortega-Gutierrez S, Molina-Holgado E, Arevalo-Martin A, et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 2005; 19:1338-1340. (Pubitemid 41113742)
87. Cabranes A, Venderova K, de Lago E, et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005; 20:207-217. (Pubitemid 41476248)
88. Sanchez AJ, Gonzalez-Perez P, Galve-Roperh I, Garcia-Merino A. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4 -benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem Pharmacol 2006; 72:1697-1706. (Pubitemid 44765005)
89. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989; 23:73-81. (Pubitemid 19125801)
90. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994; 28:209-214.
91. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404:84-87. (Pubitemid 30143137)
92. Bifulco M, Laezza C, Malfitano AM. From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Multiple Sclerosis 2007; 13:133-134. (Pubitemid 46152773)
93. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58:1404-1407. (Pubitemid 34507170)
94. Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007; 13:492-497. (Pubitemid 46559830)
95. Palazuelos J, Davoust N, Julien B, et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008; 283:13320-13329.
96. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 2004; 10:158-164. (Pubitemid 38499908)
97. Ehrhart J, Obregon D, Mori T, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005; 2:29.
98. Wiley JL, Beletskaya ID, Ng EW, et al. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther 2002; 301:679-689. (Pubitemid 34429984)
99. Zhang M, Martin BR, Adler MW, et al. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 2009; 4:249-259.
100. Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96:14228-14233. (Pubitemid 30000633)
101. Jean-Gilles L, Feng S, Tench CR, et al. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009; 287:212-215.
102. Benito C, Romero JP, Tolon RM, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007; 27:2396-2402. (Pubitemid 46340977)
103. Ali S, Lazennec G. Chemokines: novel targets for breast can cer metastasis. Cancer Metastasis Rev 2007; 26:401-420. (Pubitemid 350115103)
104. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009; 16:663-673.
105. Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 2006; 6:907-918. (Pubitemid 44851733)
106. Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nat Immunol 2008; 9:953-959.
107. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008; 15:49-58. (Pubitemid 350191028)
108. Benelli R, Lorusso G, Albini A, Noonan DM. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 2006; 12:3101-3115. (Pubitemid 44227572)
109. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 2001; 22:147-184. (Pubitemid 32706335)
110. Holman DW, Klein RS, Ransohoff RM. The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta; 1812:220-230.
111. Ubogu EE. Chemokine receptors as specific anti-inflammatory targets in peripheral nerves. Endocr Metab Immune Disord Drug Targets; 11:141-153.
112. Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006; 67:1880-1883. (Pubitemid 44900777)
113. Infante-Duarte C, Waiczies S, Wuerfel J, Zipp F. New developments in understanding and treating neuroinflammation. J Mol Med 2008; 86:975-985.
114. Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009; 124:422-427.
115. Neu IS, Metzger G, Zschocke J, Zelezny R, Mayatepek E. Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol Scand 2002; 105:63-66. (Pubitemid 34188273)
116. Dore-Duffy P, Ho SY, Donovan C. Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology 1991; 41:322-324.
117. Merrill JE, Strom SR, Ellison GW, Myers LW. In vitro study of mediators of inflammation in multiple sclerosis. J Clin Immunol 1989; 9:84-96. (Pubitemid 19103880)
118. Prosiegel M, Neu I, Mallinger J, et al. Suppression of experimental autoimmune encephalomyelitis by dual cyclooxygenase and 5-lipoxygenase inhibition. Acta Neurol Scand 1989; 79:223-226. (Pubitemid 19076994)
119. Haupts M, Smektala K, Finkbeiner T, Simmet T, Gehlen W. Immunoreactive leukotriene C4 levels in CSF of MS patients. Acta Neurol Scand 1992; 85:365-367.
120. Marusic S, Leach MW, Pelker JW, et al. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med 2005; 202:841-851. (Pubitemid 41345972)
121. Marusic S, Thakker P, Pelker JW, et al. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J Neuroimmunol 2008; 204:29-37.
122. Whitney LW, Ludwin SK, McFarland HF, Biddison WE. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 2001; 121:40-48. (Pubitemid 34008449)
123. Prosiegel M, Neu I, Vogl S, Hoffmann G, Wildfeuer A, Ruhenstroth-Bauer G. Suppression of experimental autoimmune encephalomyelitis by sulfasalazine. Acta Neurol Scand 1990; 81:237-238. (Pubitemid 20122403)
124. Neu IS, Mallinger J, Wildfeuer A, Mehlber L. Suppression of experimental autoimmune encephalomyelitis by a new specific leukotriene biosynthesis inhibitor. J Neurol 1992; 239:470-471.
125. Kihara Y, Yokomizo T, Kunita A, et al. The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2010; 394:673-678.
126. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and downmodulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007; 110:3263-3270. (Pubitemid 350106319)
127. Fretland DJ, Widomski DL, Shone RL, Levin S, Gaginella TS. Effect of the leukotriene B4 receptor antagonist, SC-41930, on experimental allergic encephalomyelitis (EAE) in the guinea pig. Agents Actions 1991; 34:172-174.
128. Gladue RP, Carroll LA, Milici AJ, et al. Inhibition of leukotriene B4-receptor interaction suppresses eosinophil infiltration and disease pathology in a murine model of experimental allergic encephalomyelitis. J Exp Med 1996; 183:1893-1898. (Pubitemid 26134329)
129. Wang L, Du C, Lv J, Wei W, Cui Y, Xie X. Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2011; 87:2336-2345.
130. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11:354-365.
131. Brack A, Rittner HL, Stein C. Immunosuppressive effects of opioids-clinical relevance. J Neuroimmune Pharmacol 2011; 6:490-450.
132. Sacerdote P. Opioids and the immune system. Palliat Med 2006; 20(Suppl 1):s9-s15. (Pubitemid 43871329)
133. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol 1998; 83:4-18. (Pubitemid 28280946)
134. Sacerdote P, Limiroli E, Gaspani L. Experimental evidence for immunomodulatory effects of opioids. Adv Exp Med Biol 2003; 521:106-116. (Pubitemid 36535169)
135. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997; 121:834-840. (Pubitemid 27260792)
136. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73:953-990. (Pubitemid 39050391)
137. Lynch JL, Alley JF, Wellman L, Beitz AJ. Decreased spinal cord opioid receptor mRNA expression and antinociception in a Theiler's murine encephalomyelitis virus model of multiple sclerosis. Brain Res 2008; 1191:180-191.
138. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol 2006; 2:95-106.
139. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci 1984; 7:223-255. (Pubitemid 14155298)
140. Lutton JD, Winston R, Rodman TC. Multiple sclerosis: etiological mechanisms and future directions. Exp Biol Med (Maywood) 2004; 229:12-20. (Pubitemid 38101674)
141. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127:1353-1360. (Pubitemid 38745513)
142. Gironi M, Martinelli V, Brambilla E, et al. Beta-endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis: effects of treatment with interferon beta. Arch Neurol 2000; 57:1178-1181. (Pubitemid 30644665)
143. Gironi M, Furlan R, Rovaris M, et al. Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74:495-497. (Pubitemid 36379374)
144. Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res 2010; 1310:154-161.
145. Jankovic BD. Enkephalins and immune inflammatory reactions. Acta Neurol 1991; 13:433-441. 148 Radulovic J, Djergovic D, Miljevic C, Jankovic BD. kappa-Opioid receptor functions: possible relevance to experimental allergic encephalomyelitis. Neuroimmunomodulation 1994; 1:236-241. 149 Zagon IS, Rahn KA, Turel AP, McLaughlin PJ. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med 2009; 234:1383-1392.
146. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008; 14:1076-1083.
147. Misra AL. Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone. NIDA Res Monogr 1981; 28:132-146. (Pubitemid 12235217)
148. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science 1983; 221:671-673. (Pubitemid 13026087)
149. Zagon IS, McLaughlin PJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci 1984; 35:409-416. (Pubitemid 14083762)
150. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 2007; 102:820-828. (Pubitemid 46496605)
151. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4:397-407. (Pubitemid 36565571)
152. Spiegel S, Milstien S. Functions of a new family of sphingosine-1- phosphate receptors. Biochim Biophys Acta 2000; 1484:107-116. (Pubitemid 30175961)
153. Chun J, Goetzl EJ, Hla T, et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002; 54:265-269. (Pubitemid 34575716)
154. Liu Y, Wada R, Yamashita T, et al. Edg-1, the G proteincoupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000; 106:951-961.
155. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427:355-360. (Pubitemid 38133663)
156. Singleton PA, Dudek SM, Chiang ET, Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 2005; 19:1646-1656. (Pubitemid 41429522)
157. Graler MH, Bernhardt G, Lipp M. EDG6, a novel G-proteincoupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics 1998; 53:164-169. (Pubitemid 28496606)
158. Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J 2005; 19:1731-1733. (Pubitemid 41429545)
159. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277:21453-21457. (Pubitemid 34952287)
160. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296:346-349. (Pubitemid 34303689)
161. Xie JH, Nomura N, Koprak SL, Quackenbush EJ, Forrest MJ, Rosen H. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol 2003; 170:3662-3670. (Pubitemid 36359236)
162. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov; 9:883-897.
163. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004; 153:108-121. (Pubitemid 38950933)
164. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005; 2:439-448.
165. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115:501-508. (Pubitemid 46188244)
166. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003; 278:47408-47415. (Pubitemid 37523181)
167. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005; 108:308-319. (Pubitemid 41691870)
168. Papadopoulos D, Rundle J, Patel R, et al. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 2010; 88:346-359.
169. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007; 323:469-475.
170. Chun J, Weiner JA, Fukushima N, et al. Neurobiology of receptor-mediated lysophospholipid signaling. From the first lysophospholipid receptor to roles in nervous system function and development. Ann N Y Acad Sci 2000; 905:110-117. (Pubitemid 30255411)
171. Kimura A, Ohmori T, Ohkawa R, et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007; 25:115-124. (Pubitemid 46052981)
172. Lee CW, Choi JW, Chun J. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res 2010; 33:1567-1574.
173. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129:3165-3172. (Pubitemid 44871433)
174. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. Remyelination in multiple sclerosis. Mult Scler 1997; 3:133-136. (Pubitemid 27390387)
175. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63:61-71. (Pubitemid 351240552)
176. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323:626-635.
177. Rao TS, Lariosa-Willingham KD, Lin FF, et al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res 2003; 990:182-194. (Pubitemid 37244074)
178. Sorensen SD, Nicole O, Peavy RD, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003; 64:1199-1209. (Pubitemid 37310753)
179. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011; 108:751-756.
180. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25:11113-11121. (Pubitemid 41747151)
181. Balatoni B, Storch MK, Swoboda EM, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOGinduced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74:307-316. (Pubitemid 47368881)
182. Alewijnse AE, Peters SL. Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 2008; 585:292-302.
183. Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2012; 337:547-556.
184. ClinicalTrials.gov Identifier: NCT01006265. http://clinicaltrials.gov/. 2009.
185. ClinicalTrials.gov Identifier: NCT01093326. http://clinicaltrials.gov/. 2010.
186. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2008; 373:286-291.
187. Dijkstra CD, van der Voort ER, De Groot CJ, et al. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology 1994; 19:135-142.
188. Musio S, Gallo B, Scabeni S, et al. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. J Immunol 2006; 176:17-26. (Pubitemid 43023244)
189. Teuscher C, Subramanian M, Noubade R, et al. Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci USA 2007; 104:10146-10151. (Pubitemid 47175277)
190. Noubade R, Milligan G, Zachary JF, et al. Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice. J Clin Invest 2007; 117:3507-3518. (Pubitemid 350097006)
191. El Behi M, Zephir H, Lefranc D, et al. Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs. J Neuroimmunol 2007; 182:80-88. (Pubitemid 46039760)
192. Pedotti R, DeVoss JJ, Youssef S, et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci USA 2003; 100:1867-1872. (Pubitemid 36254540)
193. Dimitriadou V, Pang X, Theoharides TC. Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation. Int J Immunopharmacol 2000; 22:673-684. (Pubitemid 30407021)
194. Logothetis L, Mylonas IA, Baloyannis S, et al. A pilot, open label, clinical trial using hydroxyzine in multiple sclerosis. Int J Immunopathol Pharmacol 2005; 18:771-778.
195. Koehler NK, Roebbert M, Dehghani K, et al. Up-regulation of platelet-derived growth factor by peripheral-blood leukocytes during experimental allergic encephalomyelitis. J Neurosci Res 2008; 86:392-402. (Pubitemid 351196744)
196. Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J Exp Med 2005; 202:853-863. (Pubitemid 41345973)
197. Osoegawa M, Miyagishi R, Ochi H, et al. Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2005; 161:195-198. (Pubitemid 40340889)
198. Bolton C, Turner AM, Turk JL. Prostaglandin levels in cerebrospinal fluid from multiple sclerosis patients in remission and relapse. J Neuroimmunol 1984; 6:151-159. (Pubitemid 14101479)
199. Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009; 15:633-640.
200. Esaki Y, Li Y, Sakata D, et al. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010; 107:12233-12238.
201. Sunnemark D, Eltayeb S, Wallstrom E, et al. Differential expression of the chemokine receptors CX3CR1 and CCR1 by microglia and macrophages in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis. Brain Pathol 2003; 13:617-629. (Pubitemid 37420704)
202. Trebst C, Sorensen TL, Kivisakk P, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001; 159:1701-1710. (Pubitemid 33062513)
203. Glabinski AR, Bielecki B, O'Bryant S, Selmaj K, Ransohoff RM. Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells. J Autoim mun 2002; 19:175-181. (Pubitemid 36262932)
204. Eltayeb S, Berg AL, Lassmann H, et al. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J Neuroinflammation 2007; 4:14.
205. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000; 108:192-200. (Pubitemid 30438767)
206. Sorensen TL, Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 2001; 57:1371-1376. (Pubitemid 32995713)
207. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003; 15:23-32. (Pubitemid 36092176)
208. Jiang Y, Salafranca MN, Adhikari S, et al. Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J Neuroimmunol 1998; 86:1-12. (Pubitemid 28293944)
209. Jee Y, Yoon WK, Okura Y, Tanuma N, Matsumoto Y. Upregulation of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 2002; 128:49-57. (Pubitemid 34722363)
210. Misu T, Onodera H, Fujihara K, et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 2001; 114:207-212. (Pubitemid 32184743)
211. Columba-Cabezas S, Serafini B, Ambrosini E, et al. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 2002; 130:10-21. (Pubitemid 35239989)
212. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96:6873-6878. (Pubitemid 29274977)
213. Martinez-Caceres EM, Espejo C, Brieva L, et al. Expression of chemokine receptors in the different clinical forms of multiple sclerosis. Mult Scler 2002; 8:390-395.
214. Trebst C, Konig F, Ransohoff R, Bruck W, Stangel M. CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler 2008; 14:728-733.
215. Kivisakk P, Mahad DJ, Callahan MK, et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004; 55:627-638. (Pubitemid 38544322)
216. Bielecki B, Mazurek A, Wolinski P, Glabinski A. Expression of chemokine receptors CCR7 and CCR8 in the CNS during ChREAE. Scand J Immunol 2007; 66:383-392. (Pubitemid 47394554)
217. Trebst C, Staugaitis SM, Kivisakk P, et al. CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol 2003; 162:427-438. (Pubitemid 36267850)
218. Infante-Duarte C, Weber A, Kratzschmar J, et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 2005; 19:1902-1904. (Pubitemid 41598789)
219. Sunnemark D, Eltayeb S, Nilsson M, et al. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation 2005; 2:17.
220. Omari KM, John GR, Sealfon SC, Raine CS. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005; 128:1003-1015. (Pubitemid 40675456)
221. Omari KM, John G, Lango R, Raine CS. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006; 53:24-31. (Pubitemid 43076209)
222. Filipovic R, Jakovcevski I, Zecevic N. GRO-alpha and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev Neurosci 2003; 25:279-290. (Pubitemid 37100220)
223. Glabinski AR, O'Bryant S, Selmaj K, Ransohoff RM. CXC chemokine receptors expression during chronic relapsing experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 2000; 917:135-144.
224. Sindern E, Patzold T, Ossege LM, Gisevius A, Malin JP. Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2002; 131:186-190.
225. Sorensen TL, Trebst C, Kivisakk P, et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 2002; 127:59-68. (Pubitemid 34603575)
226. Glabinski AR, Bielecki B, Ransohoff RM. Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitis. Scand J Immunol 2003; 58:81-88. (Pubitemid 36819201)
227. Nakajima H, Fukuda K, Doi Y, et al. Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Eur Neurol 2004; 52:162-168. (Pubitemid 39551725)
228. Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58:167-176.
229. Mahad D, Callahan MK, Williams KA, et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006; 129:212-223. (Pubitemid 43063772)
230. Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72:498-502.
231. Glabinski AR, Tuohy VK, Ransohoff RM. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998; 5:166-171. (Pubitemid 28417028)
232. Kennedy KJ, Strieter RM, Kunkel SL, Lukacs NW, Karpus WJ. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol 1998; 92:98-108. (Pubitemid 29015994)
233. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009; 73:2003-2010.
234. Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004; 149:182-186. (Pubitemid 38352871)
235. Krumbholz M, Theil D, Steinmeyer F, et al. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol 2007; 190:72-79. (Pubitemid 47625610)
236. Columba-Cabezas S, Serafini B, Ambrosini E, Aloisi F. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol 2003; 13:38-51. (Pubitemid 36133791)
237. Alt C, Laschinger M, Engelhardt B. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in Gprotein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 2002; 32:2133-2144. (Pubitemid 34965876)
238. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 2003; 137:210-217. (Pubitemid 36355942)
239. Carter SL, Muller M, Manders PM, Campbell IL. Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro. Glia 2007; 55:1728-1739. (Pubitemid 47612859)
240. Szczucinski A, Kalinowska A, Losy J. CXCL11 (Interferoninducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone. Eur Neurol 2007; 58:228-232. (Pubitemid 350175891)
241. Calderon TM, Eugenin EA, Lopez L, et al. A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 2006; 177:27-39. (Pubitemid 44108231)
242. McCandless EE, Piccio L, Woerner BM, et al. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol 2008; 172:799-808. (Pubitemid 351354551)
243. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129:200-211. (Pubitemid 43063771)
244. Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CG, Hancock WW. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 2000; 30:2372-2377.
245. Eltayeb S, Sunnemark D, Berg AL, et al. Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease. J Neuroimmunol 2003; 142:75-85. (Pubitemid 38368590)
246. Liang M, Mallari C, Rosser M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000; 275:19000-19008. (Pubitemid 30422866)
247. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192:899-905.
248. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000; 192:1075-1080.
249. Gaupp S, Pitt D, Kuziel WA, Cannella B, Raine CS. Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains. Am J Pathol 2003; 162:139-150. (Pubitemid 36041996)
250. Bennett JL, Elhofy A, Charo I, Miller SD, Dal Canto MC, Karpus WJ. CCR2 regulates development of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Viral Immunol 2007; 20:19-33. (Pubitemid 46608949)
251. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30:1410-1415. (Pubitemid 30311971)
252. Ni J, Zhu YN, Zhong XG, et al. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br J Pharmacol 2009; 158:2046-2056.
253. Villares R, Cadenas V, Lozano M, et al. CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues. Eur J Immunol 2009; 39:1671-1681.
254. Elhofy A, Depaolo RW, Lira SA, Lukacs NW, Karpus WJ. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. J Neuroimmunol 2009; 213:91-99.
255. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009; 10:514-523.
256. Kim JV, Jiang N, Tadokoro CE, et al. Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. J Immunol Methods 2010; 352:89-100.
257. Kuwabara T, Ishikawa F, Yasuda T, et al. CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells. J Immunol 2009; 183:2513-2521.
258. Graham KL, Zabel BA, Loghavi S, et al. Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. J Immunol 2009; 183:6717-6723.
259. Huang D, Shi FD, Jung S, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006; 20:896-905. (Pubitemid 44943947)
260. Carlson T, Kroenke M, Rao P, Lane TE, Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008; 205:811-823. (Pubitemid 351549880)
261. Kerstetter AE, Padovani-Claudio DA, Bai L, Miller RH. Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis. Exp Neurol 2009; 220:44-56.
262. Liu L, Huang D, Matsui M, et al. Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/-mice with experimental autoimmune encephalomyelitis. J Immunol 2006; 176:4399-4409. (Pubitemid 44264420)
263. Muller M, Carter SL, Hofer MJ, et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomy elitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007; 179:2774-2786.
264. Kohler RE, Comerford I, Townley S, Haylock-Jacobs S, Clark-Lewis I, McColl SR. Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. Brain Pathol 2008; 18:504-516.
265. McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol 2006; 177:8053-8064. (Pubitemid 44846323)
266. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigenspecific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001; 193:713-726.
267. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155:5003-5010.
268. Elhofy A, Wang J, Tani M, et al. Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis. J Leukoc Biol 2005; 77:229-237. (Pubitemid 40315057)
269. Fife BT, Kennedy KJ, Paniagua MC, et al. CXCL10 (IFNgamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2001; 166:7617-7624. (Pubitemid 32525644)
270. Narumi S, Kaburaki T, Yoneyama H, Iwamura H, Kobayashi Y, Matsushima K. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 2002; 32:1784-1791.
271. Klein RS, Izikson L, Means T, et al. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 2004; 172:550-559. (Pubitemid 38020512)
272. Bagaeva LV, Rao P, Powers JM, Segal BM. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol 2006; 176:7676-7685. (Pubitemid 43849068)
273. Hamann I, Zipp F, Infante-Duarte C. Therapeutic targeting of chemokine signaling in multiple sclerosis. J Neurol Sci 2008; 274:31-38.
274. ClinicalTrials.gov Identifier: NCT01199640. http://clinicaltrials.gov/. 2010.
275. Platten M, Youssef S, Hur EM, et al. Blocking angiotensinconverting enzyme induces potent regulatory T cells and modulates TH1-and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009; 106:14948-14953.
276. Stegbauer J, Lee DH, Seubert S, et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009; 106:14942-14947.
277. Schulze-Topphoff U, Prat A, Prozorovski T, et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009; 15:788-793.
278. Dos Santos AC, Roffe E, Arantes RM, et al. Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J Neuroinflammation 2008; 5:49.
279. Shin T, Kang B, Tanuma N, et al. Intrathecal administration of endothelin-1 receptor antagonist ameliorates autoimmune encephalomyelitis in Lewis rats. Neuroreport 2001; 12:1465-1468. (Pubitemid 32476149)
280. Osmers I, Smith SS, Parks BW, et al. Deletion of the G2A receptor fails to attenuate experimental autoimmune encephalomyelitis. J Neuroimmunol 2009; 207:18-23.
281. Wraith DC, Pope R, Butzkueven H, et al. A role for galanin in human and experimental inflammatory demyelination. Proc Natl Acad Sci USA 2009; 106:15466-15471.
282. Constantinescu CS, Hilliard B, Ventura E, Rostami A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 1997; 65:190-194.
283. Freire-Garabal M, Nunez MJ, Balboa J, et al. Administration of the 5-hydroxytryptamine(1A) receptor antagonist WAY100635 suppresses acute experimental allergic encephalomyelitis in Lewis rats. Neurosci Lett 2003; 342:33-36. (Pubitemid 36513903)
284. Nessler S, Stadelmann C, Bittner A, et al. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist-a putative role for substance P in CNS inflammation. J Neuroimmunol 2006; 179:1-8. (Pubitemid 44441598)
285. Bedoui S, Miyake S, Lin Y, et al. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1. receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 2003; 171:3451-3458. (Pubitemid 37254546)
286. Reinke EK, Johnson MJ, Ling C, et al. Substance P receptor mediated maintenance of chronic inflammation in EAE. J Neuroimmunol 2006; 180:117-125. (Pubitemid 44692317)
287. Tan YV, Abad C, Lopez R, et al. Pituitary adenylyl cyclaseactivating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2009; 106:2012-2017.